Pablo Rodríguez de Vera Gómez

ORCID: 0000-0002-0951-5428
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Adrenal and Paraganglionic Tumors
  • Pituitary Gland Disorders and Treatments
  • Diabetes Management and Research
  • Hormonal Regulation and Hypertension
  • Diabetes and associated disorders
  • Diabetes Treatment and Management
  • Cancer, Hypoxia, and Metabolism
  • Pancreatic function and diabetes
  • Nutrition and Health in Aging
  • Chronic Disease Management Strategies
  • Body Composition Measurement Techniques
  • Drug Transport and Resistance Mechanisms
  • Cerebral Venous Sinus Thrombosis
  • Health Promotion and Cardiovascular Prevention
  • Mobile Health and mHealth Applications
  • Ovarian cancer diagnosis and treatment
  • Cancer Immunotherapy and Biomarkers
  • Abdominal Trauma and Injuries
  • Ophthalmology and Eye Disorders
  • Parathyroid Disorders and Treatments
  • Peripheral Neuropathies and Disorders
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Helicobacter pylori-related gastroenterology studies
  • Hematological disorders and diagnostics
  • Pediatric Hepatobiliary Diseases and Treatments

Hospital Universitario Virgen Macarena
2020-2025

Background: A nationwide, prospective, multicenter, cohort study (the Disease-Related caloric-protein malnutrition EChOgraphy (DRECO) study) was designed to assess the usefulness of ultrasound rectus femoris for detecting sarcopenia in hospitalized patients at risk and define cut-off values measures. Methods: Patients according Malnutrition Universal Screening Tool (MUST) underwent handgrip dynamometry, bioelectrical impedance analysis (BIA), a Timed Up Go (TUG) test, studies. European...

10.3390/nu16111552 article EN Nutrients 2024-05-21

10.1245/s10434-025-16869-x article EN Annals of Surgical Oncology 2025-01-26

Postoperative outcomes of patients with normotensive pheochromocytomas are poorly documented. We aimed to evaluate the impact preoperative hypertension on post-operative following adrenalectomy for pheochromocytoma. An international retrospective study undergoing pheochromocytoma in 46 centers between 2012-2022 was performed. Hypertensive and were defined respectively by presence or absence history before at time diagnosis. To differences postoperative hypertensive patients, propensity score...

10.1210/clinem/dgaf154 article EN cc-by The Journal of Clinical Endocrinology & Metabolism 2025-03-06

Aim Analyze the influence of Fear Hypoglycemia (FoH) on quality life and glycemic control in adults with Type 1 Diabetes Mellitus (T1D) who use Flash Glucose Monitoring (FGM) Methods A cross-sectional study was conducted 173 T1D. FoH assessed using FH15 questionnaire, evaluated Spanish Quality Life questionnaire (EsDQOL). Glycemic analyzed through FGM-derived metrics (Ambulatory Profile) HbA1c. Multivariate multiple linear regression models were developed to analyze adjusted impact time...

10.3389/fendo.2025.1563410 article EN cc-by Frontiers in Endocrinology 2025-05-16

Objective: To assess the clinical impact on quality of life and fear hypoglycemia (FoH) flash glucose monitoring (FGM) systems in adults with type 1 diabetes (T1DM). Methods: Prospective quasi-experimental study 12-month follow up. People T1DM (18-80 years old) self-monitoring by blood capillary glycemia controls (SMBG) were included. The FH15 questionnaire, a survey validated Spanish comparable population, was used to FoH. A cut-off point 28 points for diagnosis Results: total 181...

10.1089/dia.2023.0370 article EN Diabetes Technology & Therapeutics 2024-02-05

Background Glucagon-like peptide-1 receptor-agonists (GLP-1ra), such as semaglutide, have emerged promising treatments, demonstrating sustained weight reduction and metabolic benefits. This study aims to assess the impact of oral subcutaneous semaglutide on body composition parameters in patients with T2DM obesity. Methods A 24-week quasi-experimental retrospective including adults obesity (BMI ≥ 30 kg/m²) who were treated either daily-oral or weekly-subcutaneous semaglutide. Body was...

10.3389/fendo.2024.1386542 article EN cc-by Frontiers in Endocrinology 2024-06-04

Purpose To evaluate the rate of recurrence among patients with pheochromocytomas and sympathetic paragangliomas (PGLs; together PPGLs) to identify predictors (local and/or metastatic disease). Methods This retrospective multicenter study included information 303 PPGLs in follow-up 19 Spanish tertiary hospitals. Recurrent disease was defined by development local after initial complete surgical resection. Results A total that underwent 311 resections were (288 15 PGLs). After a median 4.8...

10.3389/fendo.2023.1279828 article EN cc-by Frontiers in Endocrinology 2023-12-07

10.1245/s10434-024-16591-0 article EN Annals of Surgical Oncology 2024-12-04

The objective of our study was to determine the prevalence glycemic disorders (diabetes mellitus and prediabetes) in patients with pheochromocytomas sympathetic paragangliomas (PPGLs) identify risk factors for their development likelihood resolution after surgery. A multicentric retrospective PPGLs submitted surgery between 2000 2021 17 Spanish hospitals performed. Diabetes-specific data were collected at diagnosis, immediate- long-term postsurgical follow-up. total 229 included (218 11...

10.1530/erc-22-0218 article EN Endocrine Related Cancer 2022-09-07

Introduction: It is estimated that 30–40% of patients with apparently sporadic pheochromocytomas (PHEOs) have an inherited predisposition syndrome. The aim our study was to develop a predictive model hereditary PHEO based on the clinical, hormonal, and radiological features present at diagnosis PHEOs. Methods: A retrospective multicenter cohort PHEOs available genetic from 18 tertiary hospitals. Clinical, biochemical, were used build multivariate logistic regression model. estimation all...

10.1159/000529319 article EN Neuroendocrinology 2023-01-01

Purpose: To identify presurgical and surgical risk factors for intraoperative hypertensive crisis in patients with pheochromocytomas sympathetic paragangliomas (PGLs) (PPGLs). Methods: Retrospective multicenter cohort study of PPGLs from 18 tertiary hospitals. Intraoperative was defined as systolic blood pressure (SBP) greater than 200 mmHg lasting more 1 min postoperative SBP 180 or diastolic (DBP) 110 mmHg. Results: A total 296 surgeries were included. Alpha blockade employed 93.2% the...

10.1097/hjh.0000000000003596 article EN Journal of Hypertension 2023-10-10

10.1016/j.euf.2024.09.001 article EN European Urology Focus 2024-09-01

Objectives. The aim of this study is to investigate in depth diabetes mellitus associated with immune checkpoint inhibitors (DM-ICIs) by analysing a case series. We also evaluated the clinical impact flash glucose monitoring (FGM) systems management entity. Methods. conducted an observational cohort DM-ICIs diagnosed two hospitals Seville (Spain). Patients new diagnosis (DM) or sudden worsening preexisting DM after starting treatment ICIs, random 5 hour-postprandial C-peptide value <0.6...

10.1155/2022/4508633 article EN cc-by Journal of Diabetes Research 2022-11-04

to perform an external validation of our predictive model rule out pheochromocytoma (PHEO) based on unenhanced CT in a cohort patients with PHEOs and adenomas who underwent adrenalectomy.The was previously developed retrospective 1131 presenting adrenal lesions. In the present study, we performed another 214 available histopathological results.For validation, 115 99 were included. Our described combining variables high lipid content tumor size (AUC-ROC: 0.961) had lower diagnostic accuracy...

10.3390/cancers15143736 article EN Cancers 2023-07-23

We analyzed the effect of implementing a flash glucose monitoring (FGM) technology in public health care system with universal coverage on rate severe hypoglycemia requiring urgent adults type 1 diabetes mellitus (T1DM).

10.1089/dia.2024.0201 article EN Diabetes Technology & Therapeutics 2024-06-17
Coming Soon ...